Investors Research Corp’s Solid Biosciences SLDB Stock Holding History

Investors Research Corp’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13	Closed	-$70	–	1156
2022 Q4	$70	Sell	13 -27	-68%	-$177	﹤0.01%	1122
2022 Q3	$0	Hold	40	–	–	﹤0.01%	1133
2022 Q2	$0	Buy	+40	New	+$416	﹤0.01%	1145

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Investors Research Corp's SLDB Position: Q1 2023 in Review

Investors Research Corp sold out of Solid Biosciences (SLDB) in Q1 2023, closing a stake of 13 shares — an estimated $70 sold.

Investors Research Corp first reported a position in SLDB in Q2 2022 and held it in 3 quarters. The position peaked at $70 in Q4 2022. 39 funds tracked by Wall St. Rank hold SLDB as of Q1 2023.

Investors Research Corp reported no remaining Solid Biosciences position as of Q1 2023 after selling out during the quarter.
Investors Research Corp sold 13 Solid Biosciences shares in Q1 2023, an estimated $70.
Investors Research Corp first reported a position in Solid Biosciences in Q2 2022 and held it in 3 quarters.
Investors Research Corp's Solid Biosciences position peaked at $70 in Q4 2022.
39 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2023.

Based on Investors Research Corp's 13F filing for Q1 2023, filed 11 May 2023.